Therapy for primary and metastatic cancers

A technology of nucleic acid, seqidno., applied in immunotherapy for the treatment of metastatic tumors,
[field

Active Publication Date: 2008-05-14
SHANGHAI SUNWAY BIOTECH
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] In conclusion, the prior art has shown that it is possible to treat cancer within a limited capacity using different techniques and treatments, however many of these treatments have some significant disadvantages

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapy for primary and metastatic cancers
  • Therapy for primary and metastatic cancers
  • Therapy for primary and metastatic cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Adenoviruses are usually double-stranded DNA genome viruses that cause respiratory, intestinal, and eye infections in humans or animals. The virus that causes the common cold is an adenovirus. Oncolytic viruses of the present invention include genetically engineered adenovirus Ad5 variants. The present invention employs specific genetically engineered variants of the Ad5 virus, including S98-001 (SeqID #1) or S98-002 (SeqID #2). Although not wanting to be bound by theory, it is well known that humans infected with wild-type Ad5 are self-healing. In addition, Ad5 adenovirus has been routinely used as a vector for gene therapy because there is no report that a DNA fragment of Ad5 genome can be integrated into the genome of human cells. Thus, the present invention also employs the synchronization of injection of specific oncolytic viruses and high temperature to inhibit cancer at the site of injection and away from the site of virus injection. Although oncolytic Ad5 var...

Embodiment 2

[0099] To determine effective dosage regimens for animals (including, for example, humans) treated with the compositions and methods of the invention, five dosage levels of H101 (SEQ ID #1) were used. Recombinant adenovirus was administered by intratumoral injection to patients with advanced solid tumors. One objective was to determine the maximum resistant dose ("MTD") and safety of intratumoral injection of H101 (SEQID #1). The 5 levels of H101 (SEQID #1) used are shown in Table 2 and the dose escalation curves are shown in Figure 3. Three patients were included for each of the five independent dose levels. The MTD was determined from the dose at which 2 patients experienced DLTs including influenza-like grade 4 toxicity due to H101 (SEQ ID #1), grade 4 toxicity due to local reactions at the injection site of H101 (SEQ ID #1), or due to Any other grade 3 toxicity from H101 (SEQID #1). If one of the three patients develops a DLT, that group will treat a total of six patien...

Embodiment 3

[0105] Treatment of cancer patients with oncolytic virus S98-001 (SEQID#1) synchronized with hyperthermia. The patient's date of birth was June 10, 1943. In 1990, he was diagnosed with nasopharyngeal carcinoma. After a period of treatment with radiotherapy, the development of the primary tumor is clinically controlled. However, two tumors in the right cervical and supraclavicular regions slowly developed during these years. At the end of 2001, the two tumors were treated by radiotherapy (cobalt-60, DT 34 Gy / 17F / 24d) combined with hyperthermia. Unfortunately, these treatments did not inhibit the progression of both tumors. The patient was hospitalized in early February 2002, and a physical examination was performed on the patient prior to treatment with oncolytic virus S98-001 (SEQID#1) synchronized with hyperthermia. The patient's general physical condition was good, but his nasopharyngeal tissue was nodularly thickened and slightly congested. The surfaces of both tumors ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compositions and methods for ablating tumor cells in a subject having at least one tumor site. More specifically, the method comprises contacting the tumor cells in at least one tumor with a lytic agent in vivo, under lytic conditions, forming a treated tumor; and applying a sufficient in vivo stimulus to the treated tumor forming a stimulated tumor. Compositions and methods are included for shrinking a local tumor or a distal metastatic tumor, or both in a subject. In a preferred embodiment, the method for shrinking a tumor in a subject comprises: contacting a stimulated tumor cells in vivo with a lytic agent. The stimulus directed toward the tumor cells is capable of increasing the level of chaperone proteins in the tumor cells. The combination of lytic agents and tumor cell stimulus leads to shrinkage of the tumors that were treated directly, wherein the stimulus is either applied simultaneously or sequentially. Moreover, distal or metastatic tumors that were not-treated directly are also decreased by introducing a lytic agents into a stimulated tumor cells in a first-tumor ("the treated tumor" or "the local tumor"). The preferred method steps that include introduction of a lytic agent and stimulation of the tumor cells is repeated in order to maximize the tumor shrinkage effects.

Description

Background of the invention [0001] This application claims priority from US Provisional Patent Application Serial No. 60 / 443,095, entitled "Treatment of Metastatic Cancer," filed January 28, 2003, the entire contents of which are hereby incorporated by reference. [0002] One aspect of the invention relates to an immunotherapy for the treatment of metastatic tumors. The immunotherapeutics and methods of the invention involve simultaneous or sequential administration of physiological stress (eg, heat) and genetically engineered oncolytic viruses to the treatment area, resulting in subsequent local and distal tumor regression. [0003] Cancer can be defined as a malignant growth anywhere in the human or animal body. The spread of cancer locally or to distant parts of the body is called metastasis. An example of metastasis is the migration of cells from a malignant tumor via the bloodstream or lymph. There are a variety of cancers characterized by the uncontrolled growth of ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N7/04C12N15/861C12N15/11A61K35/76A61K35/74A61P35/00A61K35/763A61K35/765A61K35/766A61K38/19A61K38/55A61K41/00C12N7/00
CPCA61K38/191A61K35/765C12N2710/10321A61K35/74C12N2710/10343A61K38/57C12N2710/10371C12N7/00A61K38/1709A61K35/76A61K35/13A61K38/1761C12N15/86A61K38/55A61K35/763A61K35/766A61K41/0052A61P13/08A61P35/00A61P43/00Y02A50/30A61K2300/00
Inventor 胡放吴波
Owner SHANGHAI SUNWAY BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap